
Please try another search
ScinoPharm Taiwan, Ltd., together with its subsidiaries, research and develops, produces, and sells active pharmaceutical ingredients (API) to pharmaceutical companies in Taiwan, rest of Asia, Europe, India, the United States and internationally. The company provides small molecular drugs, protein drugs, complex natural molecules and derivatives, synthesis services for biochemistry molecules, such as peptides and nucleic acids; generic API manufacturing services; outsourcing services. It offers CRAM services, such as chemistry skill, analytical and regulatory, chemical process development, clinical drug substance, and consulting services for the development and manufacturing of clinical, small-scale, and commercial-stage APIs and intermediates, as well as develops peptide synthesis technologies. In addition, the company develops and manufactures western medicines and other chemical materials, albumin and oligonucleotide medicines, and injections. as well as provides biological technology services, technical, and Intellectual property rights related services. It has a strategic alliance with Baxter International Inc. to develop, manufacture, and commercialize of antiemetic drug in chemotherapy for cancer. The company was incorporated in 1997 and is headquartered in Tainan City, Taiwan.
Name | Age | Since | Title |
---|---|---|---|
Chih-Hsien Lo | 64 | 2010 | Chairman & General Chief Strategy Officer |
Wei-Te Ho | - | 2012 | Independent Director |
Wen-Chang Chang | - | 2018 | Independent Director |
Lewis Lee | - | 2021 | Independent Director |
Ming-Chuan Hsieh | - | 2018 | Representative Director |
Ya-Po Yang | 60 | 2018 | Representative Director |
Chiou-Ru Shih | - | 2010 | Representative Director |
Shiow-Ling Kao | - | 2010 | Representative Director |
Po-Ming Hou | - | 2016 | Representative Director |
Fu-Jung Lai | - | 2018 | Representative Director |
Tsung-Ping Wu | - | 2015 | Representative Director |
Jia-Horng Guo | - | 2017 | Representative Director |
Jang-Yang Chang | - | 2023 | Independent Director |
Li-Tzong Chen | - | 2018 | Independent Director |
Chin-Yuan Cheng | - | 2021 | Representative Director |
Ling-Ming Sun | - | 2023 | Representative Director |
Chyun-Yu Yang | - | 2023 | Representative Director |
Lai-Shou Su | - | 2024 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review